US-based pharmaceutical company Pfizer has submitted a new drug application (NDA) for palbociclib to the US Food and Drug Administration (FDA).
Palbociclib is an investigational oral targeted agent, which selectively inhibits cyclin-dependent kinases (CDKs) four and six to regain cell cycle control and block tumour cell proliferation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company is seeking approval for palbociclib, in combination with letrozole, to treat post-menopausal women with estrogen receptor positive (ER+) and human epidermal growth factor receptor two negative (HER2-) advanced breast cancer.
Pfizer Oncology president Garry Nicholson said: "Today’s submission marks an important milestone for Pfizer and palbociclib, and a potential advance for women with advanced breast cancer."
Pfizer has submitted the application based on the final results of PALOMA-1, a randomised, phase II trial comparing palbociclib plus letrozole with just letrozole.
PALOMA-1 was designed to assess progression-free survival in post-menopausal women with ER+, HER2- advanced breast cancer who were receiving palbociclib in combination with letrozole rather than just letrozole.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company has presented the PALOMA-1 final results at the American Association for Cancer Research (AACR) Annual Meeting 2014.
In addition, the company has started two phase III studies of palbociclib in advanced / metastatic breast cancer.
In April 2013, Palbociclib received Breakthrough Therapy designation from the FDA to treat women with advanced or metastatic ER+, HER2- breast cancer.
Pfizer noted that palbociclib is not approved for any indication in any market.
